Blood test could speed lymphoma diagnosis in resource-limited settings
For people with lymphoma, getting the right diagnosis can be a race against time. Symptoms such as swollen lymph nodes, fever, weight loss and fatigue can be signs… read more.
For people with lymphoma, getting the right diagnosis can be a race against time. Symptoms such as swollen lymph nodes, fever, weight loss and fatigue can be signs… read more.
A new report in The Lancet Haematology, led by Cleveland Clinic hematologist Bethany Samuelson Bannow, M.D., outlines practical strategies to improve diagnosis, care and outcomes globally for women and girls with hematological conditions,… read more.
Pfizer Inc. announced that the FDA has approved an expanded indication for Hympavzi (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and… read more.
AbbVie announced that the FDA has approved Decnupaz (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options…. read more.
AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple… read more.
The MHRA confirmed that it granted a UK marketing authorisation to Wayrilz (rilzabrutinib) for adults with immune thrombocytopenia (ITP) whose previous treatments have not worked sufficiently. The approval… read more.
A reduced-intensity bone marrow transplant regimen developed by Johns Hopkins physicians provides durable engraftment with low rejection rates and also may preserve fertility, according to results of a… read more.
EAHP Congress Highlights Continuous piperacillin/tazobactam infusion via elastomeric pump offers a safe, cost-effective alternative to inpatient antibiotic therapy in paediatric oncology, with measurable benefits for ward capacity, healthcare… read more.
NICE(UK): Venetoclax plus obinutuzumab can be used, within its marketing authorisation, as an option for untreated chronic lymphocytic leukaemia (CLL) in adults. It can only be used if… read more.
Agios Pharmaceuticals, Inc. announced that the FDA has approved Aqvesme (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of anemia in adults with alpha- or beta-thalassemia…. read more.
The European Commission has approved Wayrilz (rilzabrutinib), a novel, oral, reversible, Bruton’s tyrosine kinase (BTK) inhibitor, as a new treatment for immune thrombocytopenia (ITP) in adult patients who… read more.
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two… read more.